Metabolomic and Inflammatory Signatures of Symptom Dimensions in Major Depression

Competing Interest Statement

Dr. Dunlop has received research support from Acadia, Compass, Aptinyx, NIMH, Sage, and Takeda, and has served as a consultant to Greenwich Biosciences, Myriad Neuroscience, Otsuka, Sage, and Sophren Therapeutics. Dr. Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Holmusk, Johnson and Johnson (Janssen), Liva-Nova, Neurocrine Biosciences Inc., Otsuka-US, Sunovion; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, and Paddock S. Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc. and Chymia LLC. Dr. Milaneschi reported no biomedical financial interests or potential conflicts of interest. Dr. Mayberg has received consulting and intellectual property licensing fees from Abbott Labs. Dr. Penninx reports no conflicts of interest with regard to this study. Drs. Kastenmuller and Arnold are inventors on a series of patents on the use of metabolomics for the diagnosis and treatment of CNS diseases. Dr. Bhattacharyya is a co-inventor in a patent on the use of metabolomics in major depression. Dr. Craighead receives research support from the NIH and private foundations, including the Fuqua family foundations, William I. H. and Lula E. Pitts Foundation, and the Mary and John Brock Foundation. He receives book royalties from John Wiley & Sons. He is on the Board of Directors of Hugarheill ehf, an Icelandic company dedicated to prevention of depression. He serves on the Scientific Advisory Boards of Anxiety and Depression Association of America, the George West Mental Health Foundation, and AIM for Mental Health. Dr. Kristal is the inventor on general metabolomics-related IP that has been licensed to Metabolon via Weill Medical College of Cornell University and for which he received royalty payments via Weill Medical College of Cornell University and currently has an equity interest in the company. Metabolon offers biochemical profiling services and is developing molecular diagnostic assays detecting and monitoring disease. Metabolon has no rights or proprietary access to the research results presented and/or new IP generated under these grants/studies. Dr. Kristal's interests were reviewed by the Brigham and Women's Hospital and Partners Healthcare in accordance with their institutional policy. Accordingly, upon review, the institution determined that Dr. Kristal's financial interest in Metabolon does not create a significant financial conflict of interest (FCOI) with this research. The addition of this statement where appropriate was explicitly requested and approved by Dr. Kristal. All other authors reported no biomedical financial interests or potential conflicts of interest.

Funding Statement

This work was funded by grant support to Dr. Rima Kaddurah-Daouk (PI) through NIH grants R01MH108348, R01AG046171 and U01AG061359. Dr. Boadie Dunlop has support from NIH grants P50-MH077083 (PI Mayberg), R01-MH080880 (PI Craighead), UL1-RR025008 (PI Stevens), M01-RR0039 (PI Stevens) and the Fuqua Family Foundations. The PReDICT study was supported by NIH Grants numbered: P50 MH077083 and RO1 MH080880. Dr. Penninx has received research funding (unrelated to the work reported here) from Jansen Research and Boehringer Ingelheim. Drs. Gabi Kastenmuller and Matthias Arnold have support from NIH grants U01AG061359 (PI Kaddurah-Daouk), 1RF1AG059093 (PI Kaddurah-Daouk), 1RF1AG058942 (PI Kaddurah-Daouk), and 1U19AG063744 (PI Kaddurah-Daouk). Dr. Bhattacharyya had support for this work from the NIH grant R01MH108348 (PI Kaddurah-Daouk and Dunlop).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Review Board at Emory University and all patients provided written informed consent before participating.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes